Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 28;20(24):7686-95.
doi: 10.3748/wjg.v20.i24.7686.

Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues

Chien-Hung Chen  1 , Yi-Chun Chiu  1 , Sheng-Nan Lu  1 , Chuan-Mo Lee  1 , Jing-Houng Wang  1 , Tsung-Hui Hu  1 , Chao-Hung Hung  1
Affiliations
Review

Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues

Chien-Hung Chen et al. World J Gastroenterol. .

Abstract

Quantification of hepatitis B surface antigen (HBsAg) has been suggested to be helpful in the management of chronic hepatitis B (CHB) patients. Nucleos(t)ide analogs (NAs) are the therapy of choice for CHB and are used in the majority of CHB patients. NAs are able to induce hepatitis B virus (HBV) viral suppression, normalization of alanine aminotransferase (ALT) levels, and improvement in liver histology. Automated quantitative assays for serum HBsAg have recently become available, facilitating standardized quantification of serum HBsAg. This has led to increased interest in the clinical application of quantitative serum HBsAg for predicting therapeutic response to NAs. Recent studies have shown that a decline in serum HBsAg levels in patients receiving peginterferon may signal successful induction of immune control over HBV, and can therefore be used to predict therapeutic response. NA treatment typically induces a less rapid decline in HBsAg than interferon treatment; it has been estimated that full HBsAg clearance can require decades of NA treatment. However, a rapid HBsAg decline during NA therapy may identify patients who will show clearance of HBsAg. Currently, there is no consensus on the clinical utility of serum HBsAg monitoring for evaluating patient responses to NA therapy. This review focuses on recent findings regarding the potential application of HBsAg quantification in the management of CHB patients receiving NA therapy.

Keywords: Alanine aminotransferase; Hepatitis B surface antigen; Hepatitis B virus; Nucleos(t)ide analogs; Virological response.

PubMed Disclaimer

References

    1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–1500. - PubMed
    1. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science. 1993;262:369–370. - PubMed
    1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592. - PubMed
    1. Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86:1143–1150. - PubMed
    1. Blumberg BS, Sutnick AI, London WT. Hepatitis and leukemia: their relation to Australia antigen. Bull N Y Acad Med. 1968;44:1566–1586. - PMC - PubMed